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SMethods: ADAPT-DES was a prospective, multicenter, real-world registry of 8,583
pts at 11 international centers undergoing percutaneous coronary intervention (PCI)
with DES designed to determine the frequency, timing, and correlates (clinical,
angiographic and platelet reactivity) of early and late ST. In a pre-speciﬁed IVUS
substudy, outcomes were examined according to IVUS vs. angiographic guidance. We
herein report the 2-year clinical results.
Results: Average pt age was 64.0 years, and 74.1% were male. During the index
procedure, IVUS guidance was used in 3,361 (39.2%) of procedures. Pts in the IVUS-
guided group were more likely to present with an acute coronary syndrome and have
higher platelet reactivity on clopidogrel (PRU>208), and were treated with longer and
larger stents. At 2-year follow-up, deﬁnite/probable ST occurred in 22 (0.7%) pts in
the IVUS-guidance group vs 71 (1.4%) pts in the angiography-guidance group
(P¼0.002; Table). In a propensity adjusted multivariable model, IVUS guidance was
independently associated with a reduced 2-year rate of ST (HR [95%CI] ¼ 0.43 [0.25,
0.74], p¼0.002), myocardial infarction (MI; 0.65 [0.51, 0.83], p¼0.0006), clinically
driven target lesion target revascularization (TLR; 0.77 [0.62, 0.96], p¼0.02) and
target vessel revascularization (TVR; 0.83 [0.70, 0.97], p¼0.02), and all-cause death/








0.7% (22) 1.5% (71) 0.002
- Early (<30 days) 0.3% (9) 0.6% (30) 0.04
- Late (31 days - 1
year)
0.3% (10) 0.5% (24) 0.24
- Very late (1 year –
2 year)
0.15% (3) 0.45% (19) 0.01
All-cause death 3.3% (106) 4.2% (210) 0.03
Cardiac death 1.7% (54) 2.4% (119) 0.03
Myocardial
infarction
3.5% (112) 5.6% (279) <0.0001
- Peri-procedural 1.3% (44) 1.6% (84) 0.26
- Spontaneous 1.7% (52) 3.1% (151) <0.0001
- Spontaneous (<1
year)
0.8% (27) 1.7% (83) 0.001
- Spontaneous (1
year-2 year)
0.8% (25) 1.5% (68) 0.01
All-cause death/MI 6.3% (203) 9.0% (453) <0.0001
Clinically driven
TLR
4.8% (161) 6.0% (314) 0.02
Clinically driven
TVR
8.3% (279) 9.8% (510) 0.02Conclusions: These data, drawn from the largest prospective study of IVUS-guided
DES implantation to date, strongly suggest that IVUS guidance may result in
improved clinical outcomes after DES, with reduced 2-year rates of ST, TLR and
TVR, and death/MI.
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Background: The current study compared the novel Biotronik Osiro stent, eluting
sirolimus from a biodegradable polymer PLLA, applied to the surface of a thin-strut
(60 mm) Silicon-Carbide coated Cobalt-Chromium stent with the Abbot Xience
Prime stent. The aim was to compare the neointimal hyperplasia, stent appositionB22 JACC Vol 62/18/Suppl B j Ocand stent strut coverage at 9 months after procedure using IVUS and OCT imaging
techniques.
Methods: We performed a prospective, multicenter, randomized controlled study
(RCT) in 452 subjects (63.410.0 yrs) with symptomatic coronary artery disease due
to de novo stenotic lesions in native coronary arteries with a reference vessel diameter
 2.25 mm and  4.0 mm and a lesion length  26 mm. The study is registered at
clinicaltrials.gov (NCT01356888). Subjects were randomly assigned (2:1) to receive
the Osiro SES or the Xience Prime EES. In pre-speciﬁed cohort sizes, the enrolled
subjects were invited to participate in either the IVUS (N¼66) or the OCT (N¼65) sub
studies. All subjects were enrolled between July 5, 2011 - Jan 10, 2012. The IVUS
endpoints were neointimal hyperplasia and stent apposition at 9 months after proce-
dure. The OCT endpoints were neointimal hyperplasia, stent apposition and stent strut
coverage at 9 months. Baseline and 9 month follow-up images were analyzed by
independent and blinded core laboratories; IVUS by Medstar, US and OCT by Car-
dialysis, NL.
Results: IVUS and OCT conﬁrmed complete and a non-signiﬁcant difference in
apposition in both cohorts (OCT P¼0.624 and IVUS P¼0.325). IVUS and OCT
conﬁrmed less neointimal hyperplasia area at 9-months in the Osiro cohort (OCT
P¼0.024 and IVUS P¼0.043). The Osiro cohort had a higher strut coverage and lower
strut-neointima thickness at 9 months, conﬁrmed by OCT (coverage P¼0.042 and
thickness P<0.001).
Conclusions: In this RCT, the Osiro SES with a biodegradable polymer showed
comparable stent and strut apposition to the Xience Prime EES with a durable
polymer. The Osiro had a statistically signiﬁcant lower neointimal area in both the
IVUS and OCT sub studies. OCT analysis of the strut level conﬁrmed that both the
neointima thickness and percent coverage was signiﬁcantly better in the Osiro cohort.
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Background: The objective of this study is to examine the phenotypic changes of the
superﬁcial plaque occurring follow an Absorb bioresorbable vascular scaffold (Absorb
BVS) implantation.
Methods: Forty six patients (47 lesions) who underwent Absorb BVS implantation
and had serial optical coherence tomographic evaluation at baseline, and at any
follow-up time point (6 months, 1 year, 2 years or 3 years) were included in the
current analysis. Two observers identiﬁed thin capped ﬁbroatheromas (TCFA) in the
scaffolded and native segments that were located proximally or distally to the scaf-
folded segment, marked the circumferential location of the TCFA and of the calciﬁc
tissues and measured the thickness of the developed neointima at follow-up. These
data were used to construct spread-out vessel plots that portrayed the spatial location
of the detected tissues and their extent was expressed as percentage of the endoluminal
vessel wall surface.
Results: Twelve TCFA were detected at baseline in the scaffolded segments and all
were covered at follow-up. On the other hand most of the TCFA identiﬁed in native
segments (6 out of 10) did not change their phenotype at follow-up. The amount of the
superﬁcial lipid core remained unchanged at follow-up in the spread-out vessel plots
in both the scaffolded (4.9010.12% at baseline vs. 4.1810.84%, at follow-up,
P¼0.388) and native segments (28.4720.87% at baseline vs. 28.1222.00%, at
follow-up, P¼0.767). There was no difference in the thickness of the neointima
developed over TCFA and calciﬁc spots in scaffolded segments at follow-up (mean
thickness over TCFA: 22383mm vs. 21388mm over calciﬁc spots, P¼0.687).
Conclusions: Our results demonstrate that the neointimal tissue developed after
Absorb BVS implantation shields equally both lipid and calciﬁc tissues. Thus, the
Absorb BVS could be considered as a potential useful device for the invasive re-
capping of high risk plaques.
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Background: The morphological assessment of neointimal tissue using optical
coherence tomography (OCT) is highly signiﬁcant to clarify the pathophysiology of
in-stent restenosis (ISR) lesions. These OCT ﬁndings may be related to recurrence of
ISR. The aim of this study was to deﬁne the impact of OCT ﬁndings on recurrence
of ISR after various types of percutaneous coronary intervention (PCI) including plaintober 27–November 1, 2013 j TCT Abstracts/ORAL/Invasive Imaging
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33.5% (113) 21.6% (94) 0.0002




3.1 [2.9, 3.2] 2.7 [2.6, 2.8] <0.0001
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 1:00 PM–3:15 PMold balloon angioplasty (POBA), paclitaxel-coated balloon dilatation (PCB), and
drug-eluting stent (DES) implantation.
Methods: Between July 2008 and May 2012, we performed PCI for 321 ISR lesions
using POBA (67 lesions, POBA group), PCB (149 lesions, PCB group), and DES
(105 lesions, DES group). The morphological assessment of neointimal tissue at the
minimum lumen area site as to restenotic tissue structure (homogeneous, heteroge-
neous, or layered type) using OCT was performed. We examined the association
between tissue structure and mid-term (6-8 months) results including ISR and target
lesion revascularization (TLR) rates.
Results: The patients were 263 men and 58 women, and the mean age was 68.99.6
years. The mean follow-up period was 20938 days. The association of tissue
structure with ISR and TLR rates in each groups is shown in the ﬁgure. The ISR rates
of lesions with homogeneous and layered structure were signiﬁcantly lower in the
PCB and DES groups than in the POBA group, whereas there were no differences
between 3 groups in heterogeneous structure.Plaque volume, % 56.1 [55.2, 57.1] 58.1 [57.3, 58.9] 0.003
Dense calcium
volume, %
11.8 [11.0, 12.7] 9.5 [8.9, 10.1] <0.0001
Plaque rupture 26.6 % (107) 38.4% (197) 0.0002
TCFA at MLA site 10.7% (43) 14.2% (73) 0.12
Any lesion TCFA 45.2% (182) 56.1% (288) 0.001
Calciﬁed-ThCFA at
MLA site





SConclusions: The morphological assessment of ISR tissue using OCT might suggest
favorable types of PCI for ISR lesions.
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Background: Previous IVUS studies, due to small size, were not able to establish
a relation between statin use and its impact on plaque composition by grayscale and
VH-IVUS.
Methods: ADAPT-DES was a prospective multicenter study of 8,583 pts undergoing
percutaneous coronary intervention (PCI) using drug-eluting stents. A pre-speciﬁed
grayscale and VH-IVUS sub-study enrolled 2,064 pts. Pre-PCI imaging of 773 pts
identiﬁed 907 culprit lesions. Pts with vs without statin use prior to hospital admission
were compared.
Results: Overall, 43.6% (377) of pts were treated with statins prior to admission. Pts
using statins were older and had a higher prevalence of risk factors such as diabetes
(33% vs 20%, p<0.0001), hypertension (90% vs 59%, p¼0.02), and renal insufﬁ-
ciency (creatinine clearance <60 ml/min, 14% vs 7%, p¼0.001). At admission, statin
pts were frequently taking medications such as aspirin, ACEI/ARB, and beta-blockers
(all p<0.0001). Statin pts were more likely to present with more stable angina, while
non-statin pts more frequently presented with ST-segment elevation (STE) and non-
STE acute coronary syndromes (Table). Statin pts were more likely to have angio-
graphic 3-vessel disease and calciﬁcation. Grayscale and VH-IVUS ﬁndings showed
that statin pts had slightly larger minimum lumen area (MLA) along with less plaque
burden, but with more dense calcium (DC). Statin pts had more calciﬁed thick-cap
ﬁbroatheromas (ThCFA: necrotic core >10%, conﬂuent DC >10%, well-deﬁned
ﬁbrous cap), but fewer thin-cap ﬁbroatheromas (TCFAs) or plaque ruptures.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Chronic statin use in PCI patients was associated with more stable
clinical presentation and IVUS ﬁndings consistent with greater lesion stability (fewer
VH-TCFAs and plaque ruptures, more ThCFAs) compared to pts with CAD who were
not taking statins.
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Background: Chronic total occlusions of the vessels in the periphery are often
encountered and present signiﬁcant technical challenges. The presence of occlusive
disease is associated with higher rates of failed re-canalization and worse long term
results. Currently, subintimal dissection and re-entry techniques are commonly
used to treat these challenging lesions. For all subsequent therapy, including
angioplasty, stenting and atherectomy, the ability to cross occlusions while staying
within the true lumen is preferred. Devices and techniques which allow re-
canalization through the true lumen represent an important and unmet clinical need.
Forward-looking IVUS (FL.IVUS) is a new technology that has been developed to
provide real-time therapy guidance while crossing challenging peripheral
occlusions.
Methods: A non-randomized, non-blinded, multi-center, ﬁrst-in-man, four-phase,
prospective study was performed to assess the safety and feasibility of the Forward-
looking IVUS system in subjects with peripheral artery disease undergoing endo-
vascular therapy. In the fourth phase of this study, the FL.IVUS device was used to
provide real-time guidance while crossing CTOs in iliac and femoral vessels.
Results: Twenty cases were completed at three centers to assess the safety and
feasibility of the Forward-looking IVUS system in crossing peripheral chronic total
occlusions. The FL.IVUS catheter provided real-time images of the vessel and
occlusion. These images were used for guidewire placement and to conﬁrm true lumen
position while crossing the CTOs. Two cases from the ﬁrst-in-human series will be
presented to highlight the clinical utility and imaging performance of the FL.IVUS
system.
Conclusions: A novel Forward-looking IVUS device was used to provide real-time,
intraluminal guidance for the treatment of CTOs in the iliac and femoral arteries. This
ﬁrst-in-human clinical series demonstrates the preliminary safety and feasibility of this
novel imaging modality for the endovascular treatment of complex peripheral artery
disease. Future directions for the technology include improved catheter performance
and new imaging and software features.acts/ORAL/Invasive Imaging B23
